CRISPR Therapeutics (NASDAQ:CRSP) Rating Reiterated by Guggenheim

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “neutral” rating reiterated by analysts at Guggenheim in a research report issued on Friday, MarketBeat Ratings reports.

Several other research firms have also recently commented on CRSP. Wells Fargo & Company lowered their target price on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research note on Monday, June 17th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Barclays lowered their target price on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Finally, Robert W. Baird lifted their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $75.71.

CRISPR Therapeutics Price Performance

CRSP stock opened at $54.01 on Friday. The company’s 50 day simple moving average is $56.72 and its 200-day simple moving average is $64.51. The firm has a market capitalization of $4.59 billion, a PE ratio of -19.86 and a beta of 1.78. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. CRISPR Therapeutics’s revenue was down 99.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.67) EPS. As a group, sell-side analysts anticipate that CRISPR Therapeutics will post -5.51 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares in the company, valued at approximately $378,327.05. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CRSP. Blue Trust Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter worth $32,000. Bourgeon Capital Management LLC raised its stake in shares of CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its stake in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $41,000. Finally, NBC Securities Inc. raised its stake in shares of CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.